| WHO | World Health Organization |
| CNS | Central nervous system |
| ALL | Acute lymphoblastic leukemia |
| AML | Acute myeloid leukemia |
| JAK | Janus kinases |
| STAT | Signal transducer and activator of transcription |
| PI3K | Phosphoinositide 3-kinases |
| ALK | Anaplastic lymphoma kinase |
| NF1 | Neurofibromatosis type 1 |
| PTEN | Phosphatase and tensin homolog |
| FLT3 | FMS-like tyrosine kinase 3 |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha or p110α |
| PIK3R1 | Phosphoinositide-3-kinase regulatory subunit 1 |
| CDKN2A | Cyclin-dependent kinase Inhibitor 2A |
| TME | Tumor microenvironment |
| TILs | Tumor-infiltrating lymphocytes |
| Tregs | Regulatory T cells |
| NK cells | Natural killer cells |
| DCs | Dendritic cells |
| MDSCs | Myeloid-derived suppressor cells |
| ECM | Extracellular matrix |
| mAbs | Monoclonal antibodies |
| CAR | Chimeric antigen receptor |
| TAMs | Tumor-associated macrophages |
| TMB | Tumor mutational burden |
| LGG | Low-grade gliomas |
| HGG | High-grade gliomas |
| IFNγ | Interferon-gamma |
| CSF1R | Colony stimulating factor 1 receptor |
| CTLs | Cytotoxic T lymphocytes |
| PMN | Polymorphonuclear |
| PD-L1 | Programmed death ligand-1 |
| IL6 | Interleukin 6 |
| ES | Ewing sarcoma |
| TNF-α | Tumor necrosis factor-alpha |
| CTLA-4 | Cytotoxic T-lymphocyte-associated protein 4 |
| PD-1 | Programmed cell death protein 1 |
| MRD | Minimal residual disease |
| HSCT | Hematopoietic stem cell transplantation |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| SCT | Stem-cell transplantation |
| COG | Children’s oncology group |
| ADCC | Antibody-dependent cellular cytotoxicity |